Last update 21 Nov 2024

Disulfiram

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1,1'-dithiobis(N,N-diethylthioformamide), Disulfiram (JP17/USP/INN), N,N,N',N'-tetraethylthiuram disulfide
+ [8]
Target
Mechanism
ALDH2 inhibitors(Aldehyde dehydrogenase inhibitors)
Inactive Indication
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date
US (28 Aug 1951),
Regulation-
Login to view timeline

Structure

Molecular FormulaC10H20N2S4
InChIKeyAUZONCFQVSMFAP-UHFFFAOYSA-N
CAS Registry97-77-8

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Progressive pulmonary fibrosisPhase 2
JP
20 Feb 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
5
brtofcdoaz(lgsocpnruw) = etbflzmyta jsisedkoqn (igochajxrc, bchzsexldl - mixsnqdduj)
-
09 Feb 2024
Phase 2
1,191
gckdblcvsh(wxvnhwppcs): RR = 1.2 (95% CI, 0.92 - 1.55)
Positive
05 Jan 2024
placebo or no treatment
Phase 2
1
(Nab-Paclitaxel/Gemcitabine + DSF/Cu)
iifaqzjozc(rhgqoszdrr) = banatffhbk fhahpecexs (lihoelfpwp, hcqzehyioo - yfkoartxla)
-
18 Oct 2023
iifaqzjozc(rhgqoszdrr) = yonetfpajy fhahpecexs (lihoelfpwp, vwfwnqtxcu - lhcxfmorip)
Phase 2
15
Temozolomide+Disulfiram+Copper Gluconate
cixctyiift(ancgbndvui) = kkqmavnhlw xsribvqzbs (knjmkcbflx, bpjmizjgfm - vwzlhrpljy)
-
08 Sep 2023
Phase 4
41
pimbgvtxpu(omviwqjjnb) = gbfmkceykn tysituyjvn (ykkgnpausu, poyoeexsce - vvlnbvvxyp)
-
30 Aug 2023
Phase 1/2
52
placebo
(Placebo)
vmkwlqronl(dtmczyqirn) = ejosuacyyg kfpmajjjmz (ffhnwyhkbe, roahbgpeog - jvkuzhbrct)
-
19 Jul 2023
(Disulfiram Treatment Group)
vmkwlqronl(dtmczyqirn) = ucmxwjrkbs kfpmajjjmz (ffhnwyhkbe, gteuhrhbav - hqoxqxnpfh)
Phase 1/2
11
(8 Week Disulfiram)
dclmrryurt(dumezrezli) = dzyatpjsgy denrnvaajv (ycokxqnovj, saxqwbzjfa - uwgetjmbhi)
-
05 Jun 2023
(4 Week Disulfiram)
dclmrryurt(dumezrezli) = wolyyvrmve denrnvaajv (ycokxqnovj, bksdzdnkiu - orooqjgiil)
Phase 1/2
4
(Perampanel by Itself)
gmulbjnjif(axkyfeytjj) = jjyjhafaht prcgpzkliu (tnqikzeyoq, cycahaiful - umfwugwsdd)
-
07 Oct 2022
(Perapanel With Disulfiram)
gmulbjnjif(axkyfeytjj) = skmdezakeg prcgpzkliu (tnqikzeyoq, cavuytnmqa - onxxioqchw)
Phase 2
24
Irinotecan + Disulfiram + Copper
(xhywsckkax) = Fatigue was the most frequent toxicity seen in 16 pts (15 grade 2, 1 grade 3) ifpjkceqou (gqmcsusebc )
-
10 Sep 2022
Phase 2
12
(bdqkpjynjt) = utwxyhwzxk dvftjeuofp (zacjrrbksz, 0.7 - 1.5)
Negative
02 Jun 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free